Amgen (AMGN) Interest Expenses (2009 - 2026)
Amgen (AMGN) posted quarterly Interest Expenses of $2.2 billion for Q1 2026, little changed year-over-year from $2.2 billion in Q1 2025, and up 236.91% quarter-over-quarter from $653.0 million in Q4 2025.
Amgen (AMGN) Interest Expenses (2009 - 2026) Analysis & Trends
Amgen's Interest Expenses history runs 18 years deep, the most recent figure standing at $2.2 billion for Q1 2026.
- In Q1 2026, Interest Expenses changed 0.0% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (changed 0.0% YoY), while the FY2025 annual figure was $2.9 billion, down 12.12% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.2 billion, up from $653.0 million in the prior quarter.
- The five-year high for Interest Expenses was $2.9 billion in Q1 2024, with the low at $415.0 million in Q4 2022.
- The 5-year median for Interest Expenses is $2.1 billion (2023), against an average of $1.9 billion.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 97.83% in 2023, then decreased 24.14% in 2025.
- Amgen's Interest Expenses stood at $415.0 million in 2022, then soared by 97.83% to $821.0 million in 2023, then declined by 9.01% to $747.0 million in 2024, then decreased by 12.58% to $653.0 million in 2025, then jumped by 236.91% to $2.2 billion in 2026.
- Business Quant data shows AMGN's Interest Expenses at $2.2 billion in Q1 2026, $653.0 million in Q4 2025, and $2.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 462.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 435.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 673.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 247.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -244.19 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -333.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 673.00 Mn |
| Jun 30, 2026 | 673.00 Mn |
| Mar 31, 2026 | 2.20 Bn |
| Mar 31, 2026 | 2.20 Bn |
| Dec 31, 2025 | 653.00 Mn |
| Dec 31, 2025 | 653.00 Mn |
| Sep 30, 2025 | 2.30 Bn |
| Sep 30, 2025 | 2.30 Bn |
| Jun 30, 2025 | 2.30 Bn |
| Jun 30, 2025 | 2.30 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Mar 31, 2025 | 2.20 Bn |
| Dec 31, 2024 | 747.00 Mn |
| Dec 31, 2024 | 747.00 Mn |
| Sep 30, 2024 | 2.90 Bn |
| Sep 30, 2024 | 2.90 Bn |
| Jun 30, 2024 | 2.90 Bn |
| Jun 30, 2024 | 2.90 Bn |
| Mar 31, 2024 | 2.90 Bn |
| Mar 31, 2024 | 2.90 Bn |